$2 / month

Comment and reply across TML.

Start or manage membership

Most pulsed

Latest from other desks

tml.the modern leap
Health / Medical Research

Mayo Study Finds Some BRCA2 Variants Carry Lower Risk

Mayo Clinic researchers studied 70 BRCA2 variants that only partly disrupt the gene and estimate a 20 to 25 percent lifetime breast cancer risk for carriers, against 50 to 70 percent for the more common harmful variants.

TML Health DeskNov 18, 4:08 PM ET · 2 min read

Edited and fact-checked by Stephen Sprague

A Hologic mammography unit in a screening room (archive). Photo: themozhi's pixel displays, via Flickr (CC BY 2.0).
Summary

The Mayo team's mapping continues across BRCA1 and BRCA2, and carriers get variant-specific risk figures as each new hypomorph is confirmed.

Tap a passage. React to the part that matters.

A woman who learns she carries a harmful BRCA2 variant usually gets one broad risk range. A Mayo Clinic team has now separated out 70 variants that sit well below it.

The researchers call the group hypomorphic variants because each one only partially disrupts the gene's function instead of disabling it. In the study, published in Nature Communications, the team measured how each variant changes BRCA2 activity and checked the results against hereditary cancer testing data from large numbers of people, in work done with Ambry Genetics.

Their estimate puts lifetime breast cancer risk at 20 to 25 percent for people who inherit one of these variants. The more common harmful BRCA2 variants carry a lifetime risk of 50 to 70 percent, and the paper gives the lower group its own label, reduced penetrance pathogenic variants, so reports stop treating every harmful result as the same number.

"This shows that not all harmful BRCA2 variants carry the same level of breast cancer risk," says Fergus Couch, Ph.D., a breast cancer researcher at Mayo Clinic Comprehensive Cancer Center. "Understanding these differences could help us better match cancer prevention and screening strategies to an individual's actual risk."

Screening does not fall away at the lower figure, and the researchers say carriers may still qualify for and benefit from regular mammograms and breast MRI. The sharper number matters most around risk-reducing surgery, where a patient weighing an irreversible operation deserves the variant-specific estimate rather than the widest range on the chart.

These figures come from laboratory function assays and existing testing records, not from a prospective trial that follows carriers over time, and readers should treat them as estimates with that limit attached. The team also reports that some tumors linked to these variants may respond to PARP inhibitors, with tumor testing as the way to check, and the mapping work continues across BRCA1 and BRCA2.

Sources

The conversation

A little more perspective.

Reading is free. Verified members can comment and reply for $2 a month.

The conversation.

Loading comments…

Keep your curiosity going.

Some links here are affiliate links. If you buy through one, we might make a commission — it never changes what you pay. As an Amazon Associate I earn from qualifying purchases.